Clinical Trials Sponsored by Calosyn Pharma, Inc.

Total 2363 results

EIP Pharma Inc

Completed

A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Netherlands
Astellas Pharma Inc

Completed

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of ASP1941 in Adult Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, India, Philippines, Colombia, Mexico
Astellas Pharma Inc

Completed

A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-Results Survey of Regnite

Restless Legs Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

Healthy Subjects

Japan
Astellas Pharma Inc

Completed

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Chronic Kidney Disease

Japan
Yuyu Pharma, Inc.

Completed

Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder) (ADHD)

Mental Disorders

Korea, Republic of
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

Chronic Constipation

Japan
Astellas Pharma Inc

Completed

Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

Type 2 Diabetes Mellitus

Japan
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
Astellas Pharma Inc

Completed

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients (STELLALONGTERM)

Type 2 Diabetes

Japan
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
Astellas Pharma Inc

Completed

Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder

Overactive Bladder | Neurogenic Detrusor Overactivity

Belgium, Canada, Denmark, Netherlands, Poland, Turkey, United Kingdom
Astellas Pharma Inc

Completed

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

Chronic Kidney Disease | Hyperphosphatemia Undergoing Hemodialysis

Japan
Astellas Pharma Inc

Completed

Pharmacokinetics of Oral Mirabegron With Different Release Rates Versus Intravenous (IV) Mirabegron

Healthy | Pharmacokinetics of Mirabegron

United States
Astellas Pharma Inc

Completed

Special Drug Use Surveillance of Irribow in Female Patients

Diarrhea-predominant Irritable Bowel Syndrome

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate

Rheumatoid Arthritis

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects

Healthy Volunteers

Japan
Astellas Pharma Inc

Completed

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile

Japan
Astellas Pharma Inc

Terminated

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Korea, Republic of, Belgium, United States, Hong Kong, Singapore, Taiwan, Germany, Spain, France, Italy
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Urinary Incontinence

United States, Canada
Astellas Pharma Inc

Completed

A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Astellas Pharma Inc

Completed

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Candidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal Candidiasis

United States, South Africa
ZS Pharma, Inc.

Completed

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Hyperkalemia

United States, Germany, Australia, Netherlands, South Africa, Romania, United Kingdom
Astellas Pharma Inc

Completed

Method of Pre-treatment for Application of QUTENZA Capsaicin 8% Patch (LIFT)

or Peripheral Nerve Injury (PNI) | Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN)

Belgium, Czechia, Denmark, Ireland, Norway, Slovakia, United Kingdom
EIP Pharma Inc

Completed

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

Alzheimer's Disease

United States
Antares Pharma Inc.

Completed

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

Hypogonadism

United States
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Overactive Bladder

Japan
Flex Pharma, Inc.

Withdrawn

Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

Amyotrophic Lateral Sclerosis | Fasciculation

United States
Antares Pharma Inc.

Completed

Pharmacokinetic Study of Testosterone Enanthate

Hypogonadism

United States
Astellas Pharma Inc

Completed

Study of FK463 for the Treatment of Invasive Aspergillosis

Aspergillosis

United Kingdom, Austria, France, Germany, Italy, Poland, Spain, Sweden
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (SCORPIO)

Urinary Bladder, Overactive

Australia, Belgium, France, Spain, Sweden, Bulgaria, Romania, Italy, Greece, South Africa, Austria, Poland, United Kingdom, Hungary, Denmark, Netherlands, Switzerland, Ireland, Lithuania, Russian Federation, Germany, Latvia, Slovakia, Finlan... and more
Astellas Pharma Inc

Completed

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (TAURUS)

Urinary Bladder, Overactive

Canada, Poland, Belgium, Spain, Sweden, United States, Romania, Italy, France, Austria, United Kingdom, Germany, Hungary, Australia, Denmark, Netherlands, Switzerland, Lithuania, Russian Federation, Latvia, South Africa, Slovakia, F... and more
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Astellas Pharma Inc

Completed

Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation (DIAMOND)

Liver Transplantation

Argentina, Austria, Belarus, Belgium, Brazil, Canada, Colombia, Czechia, Finland, France, Germany, Hungary, Ireland, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Sweden, Switzerland, United Kingdom
Astellas Pharma Inc

Completed

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection (OSAKA)

Kidney Transplantation

Belgium, France, Germany, Italy, Spain, Greece, Switzerland, United Kingdom, Ireland, South Africa, Romania, Sweden, Russian Federation, Austria, Hungary, Poland, Portugal, Netherlands, Argentina, Czechia, Norway, Slovakia
UMN Pharma Inc.

Completed

A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers

Healthy

Japan
UMN Pharma Inc.

Completed

A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older

Influenza | Vaccine

Japan
UMN Pharma Inc.

Completed

A Study to Evaluate Intramuscular ASP7374

Influenza | Vaccine

Japan
ZS Pharma, Inc.

Completed

POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study (PORTEND)

Hyperkalemia

United States
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation (MAIN)

Liver Transplantation

Korea, Republic of
Akros Pharma Inc.

Completed

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Skin Diseases | Psoriasis | Plaque Psoriasis

Canada
Astellas Pharma Inc

Completed

Comparison of Two Tacrolimus Based Immunosuppressive Regimens in Recipients Receiving Marginal Donor Kidneys (TIGRE)

KIDNEY TRANSPLANTATION

Italy

3

Subscribe